The present invention relates to a composition comprising as active ingredients an extract of Cetraria islandica, silver and/or a salt thereof and hyaluronic acid and/or a salt thereof. The present invention further relates to the use of such composition for the treatment of skin and/or mucous membrane diseases.

The present invention relates to a composition comprising as active ingredients an extract of Cetraria islandica, silver and/or a salt thereof and hyaluronic acid and/or a salt thereof. The present invention further relates to the use of such composition for the treatment of skin and/or mucous membrane diseases.

A plasma activated ophthalmic solution generating device operable to generate a therapeutic ophthalmic solution for curing epidemic keratoconjunctivitis includes a plasma generating electrode operable to generate a plasma activated ophthalmic solution for epidemic keratoconjunctivitis, wherein the plasma generating electrode is arranged surrounding an insert space where a unit dose ophthalmic eyedrop container with a container body, which seals a certain solution in a sterile state, is inserted; a power supply unit; and a high voltage generating unit, which is connected to the power supply unit, operable to be supplied with power source from the power supply unit and to apply high voltage electric current to the plasma generating electrode. This configuration makes it possible to provide a novel and effective therapeutic ophthalmic solution for epidemic keratoconjunctivitis (EKC).

Silver and titanium oxide nanoparticles produced with Fomes fomentarius or Fomitopsis pinicola aqueous extracts and methods for treating bacterial infections or cancer using them.

Provided herein are compositions including polymeric binder or a salt thereof, high molecular weight polymer, pharmaceutically active agent and a low molecular weight cross-linking agent, methods for using the compositions to coat a substrate, and methods for making the compositions. Alternatively, the composition may include a polymeric binder or a salt thereof, high molecular weight polymer and a pharmaceutically active agent. In particular, the substrate may form part of an apparatus on which it would be beneficial to limit biofouling and/or protein binding.

In one aspect, provided is an aqueous antiseptic composition comprising glycerin 8.5-16% by weight; caprylyl glycol 0.45-3% by weight; and a first ingredient; wherein the first ingredient is acrylates/C10-30 about 0.01-0.1% by weight or ethoxydiglycol about 1-5% by weight. The glycerin, the caprylyl glycol and the first ingredient taken together form a first component. A sum of the first component is more than 13% by weight of the antiseptic composition. Other exemplary embodiments are also described. In certain embodiments, provided is an antiseptic composition useful for making skin or hand sanitizers that have a long-lasting, great antiseptic efficacy but at the same time having skin-moisturizing, low toxicity and low skin-irritating, hypo-allergenic properties, low inflammability, and low production cost.

In one aspect, provided is an aqueous antiseptic composition comprising glycerin 8.5-16% by weight; caprylyl glycol 0.45-3% by weight; and a first ingredient; wherein the first ingredient is acrylates/C10-30 about 0.01-0.1% by weight or ethoxydiglycol about 1-5% by weight. The glycerin, the caprylyl glycol and the first ingredient taken together form a first component. A sum of the first component is more than 13% by weight of the antiseptic composition. Other exemplary embodiments are also described. In certain embodiments, provided is an antiseptic composition useful for making skin or hand sanitizers that have a long-lasting, great antiseptic efficacy but at the same time having skin-moisturizing, low toxicity and low skin-irritating, hypo-allergenic properties, low inflammability, and low production cost.

In one aspect, provided is an aqueous antiseptic composition comprising glycerin 8.5-16% by weight; caprylyl glycol 0.45-3% by weight; and a first ingredient; wherein the first ingredient is acrylates/C10-30 about 0.01-0.1% by weight or ethoxydiglycol about 1-5% by weight. The glycerin, the caprylyl glycol and the first ingredient taken together form a first component. A sum of the first component is more than 13% by weight of the antiseptic composition. Other exemplary embodiments are also described. In certain embodiments, provided is an antiseptic composition useful for making skin or hand sanitizers that have a long-lasting, great antiseptic efficacy but at the same time having skin-moisturizing, low toxicity and low skin-irritating, hypo-allergenic properties, low inflammability, and low production cost.

Medicinal clay compositions and pharmaceutical compositions containing the same are disclosed. The medicinal clay compositions provide a protective barrier for the clay allowing manufacturing, storage and use that protects the medicinal clay from moisture and hydration that would otherwise prematurely activate the clay. The medicinal clay compositions allow use of medicinal clays in various delivery systems and types of therapeutic compositions, including foams, hydrocolloids, electrospinning, films, pastes, and the like. Methods of preparing the medicinal clay compositions and methods of use are also disclosed. Methods of using the medicinal clay compositions, pharmaceutical compositions, and cation sources to reduce microbial populations on a subject and/or remove chloride from exudate from a tissue or organ in need of treatment are also disclosed.

Medicinal clay compositions and pharmaceutical compositions containing the same are disclosed. The medicinal clay compositions provide a protective barrier for the clay allowing manufacturing, storage and use that protects the medicinal clay from moisture and hydration that would otherwise prematurely activate the clay. The medicinal clay compositions allow use of medicinal clays in various delivery systems and types of therapeutic compositions, including foams, hydrocolloids, electrospinning, films, pastes, and the like. Methods of preparing the medicinal clay compositions and methods of use are also disclosed. Methods of using the medicinal clay compositions, pharmaceutical compositions, and cation sources to reduce microbial populations on a subject and/or remove chloride from exudate from a tissue or organ in need of treatment are also disclosed.